Board of Directors
Frank K. Bedu-Addo, Ph.D., President and CEO. - Dr. Bedu-Addo is a veteran executive and bio-entrepreneur with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations as well as emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive member of KBI BioPharma, Inc. As Vice President of Drug Development he oversaw all business and drug development operations. Before being hired by KBI, he successfully started and managed Cardinal Health’s east coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was also an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions he participated in the development of numerous drugs, including antiviral and anticancer drugs. He serves on the board of directors of BioConvergence, LLC, an early stage biotechnology company. Dr. Bedu-Addo obtained his M.S. in chemical engineering and Ph.D. in pharmaceutics from the University of Pittsburgh.
De Lyle W. Bloomquist (Board Observer) – Mr. De Lyle Bloomquist is currently the Worldwide President of Tata Chemicals, Ltd. He was formerly the President, CEO and Director of General Chemical Industrial Products Inc., a $425 million mining company, which he was instrumental in selling to Tata Chemicals Ltd. for $1.005 billion in March 2008. During his 20 year career in business, he has held positions in finance and accounting, manufacturing, sales & marketing, logistics, and general management. He has experience taking companies public & private, and raising financing in the public markets as well as with banks and private investors. Mr. Bloomquist currently serves on the Boards of Directors for ANSAC and Brunner Mond, and until February 2008, Oglebay Norton. He has served on a number of Board committees including compensation, audit, and government affairs. He is a co-founder and partner of Asklepios Capital LLC, an angel investment company and principal investor in PDS Biotechnology Corporation.
Ronald K. Labrum - Ronald K. Labrum is currently the Chief Executive Officer of Fenwal, Inc., Chicago, IL, a Transfusion Therapies business that was acquired from Baxter International, Inc. He was formerly CEO of Cardinal Health’s Healthcare Supply Chain Services which includes medical products distribution, pharmaceutical distribution, nuclear pharmacy services and the specialty distribution businesses of Cardinal Health. Ron was also previously Chairman and CEO of Integrated Provider Solutions and Cardinal Health - International. Prior to February 2004, he was executive vice president of Cardinal Health and Group President of the Medical Products and Services segment. Ron joined Cardinal Health in 1999 with the acquisition of Allegiance Healthcare Corporation, originally American Hospital Supply Corp., where he was president of Allegiance Manufacturing and Distribution. He holds a bachelor's degree in business administration from Utah State University.
Kent M. Payne, Ph.D. (Vice President & General Manager) - Dr. Kent M. Payne is currently Vice President and General Manager and holds P&L responsibility for Catalent Biologics within Catalent Pharma Solutions. Beginning in 2001, he was instrumental in developing the Pharmaceutical Development outsourcing business within Cardinal Health, a Fortune 19 company. Previously he worked for the Novartis Institute for Biomedical Research, and prior to that held positions at G.D. Searle where he was also an Associate Fellow. He is a co-founder and partner of Asklepios Capital LLC, an angel investment company. He also serves as Non-Executive Board Chairman for PDS Biotechnology Corporation. As a business leader, he has been successful leading start-up, growth, and turn-around situations and is an advocate of Operational Excellence and Lean/Six Sigma principles.
Thomas J. Stuart – Thomas J. Stuart is an independent consultant, providing business advisory services to companies in the pharmaceutical and healthcare industries. Prior to establishing his own firm at the end of 2010, Mr. Stuart was Group President, Oral Technologies with Catalent Pharma Solutions, Inc., a company formed in 2007 as a result of the $3.3 billion purchase of the Pharmaceutical Technologies and Services business of Cardinal Health, Inc. by Blackstone Group. Previously, Mr. Stuart was President of Global Contract Manufacturing and Services at Cardinal Health, and held other executive leadership and financial management roles with both Cardinal Health and R.P. Scherer Corporation beginning in 1990. Mr. Stuart was a Certified Public Accountant with Arthur Andersen & Co. from 1983 to 1990, where he last served as a senior manager in the Detroit office. He has a B.S. degree in accounting and finance, graduating with honors from Michigan State University in East Lansing, Michigan.